⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7669693 | 0.96 | — | — | |
| SCHEMBL17970603 | 0.84 | — | — | |
| SCHEMBL8590083 | 0.83 | — | — | |
| SCHEMBL16409171 | 0.69 | — | — | |
| SCHEMBL27175 | 0.67 | — | — | |
| SCHEMBL6048331 | 0.67 | ALDH1A1 (0.42) | — | |
| SCHEMBL3708709 | 0.67 | ALDH1A1 (0.42) | — | |
| SCHEMBL12212851 | 0.67 | — | — | |
| SCHEMBL21624980 | 0.67 | ALDH1A1 (0.42) | — | |
| SCHEMBL6451274 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230140014-A1 | Methods and Systems for Prophylactically Preventing, Slowing the Progression of, or Treating Cerebral Amyloid Angiopathy, Alzheimer’s Disease, and/or Acute Stroke | HDL THERAPEUTICS, INC. | 2023-05-04 | — | — | US | claimed |
| WO-2023064794-A1 | METHODS AND SYSTEMS FOR PROPHYLACTICALLY PREVENTING, SLOWING THE PROGRESSION OF, OR TREATING CEREBRAL AMYLOID ANGIOPATHY, ALZHEIMER'S DISEASE AND/OR ACUTE STROKE | HDL THERAPEUTICS, INC. (US) | 2023-04-20 | — | — | WO | claimed |
| EP-3790573-A1 | METHODS FOR PROPHYLACTICALLY PREVENTING, SLOWING THE PROGRESSION OF, OR TREATING CEREBRAL AMYLOID ANGIOPATHY, ALZHEIMER'S DISEASE AND/OR ACUTE STROKE | HDL Therapeutics, Inc. (US) | 2021-03-17 | — | — | EP | claimed |
| WO-2019217897-A1 | METHODS FOR PROPHYLACTICALLY PREVENTING, SLOWING THE PROGRESSION OF, OR TREATING CEREBRAL AMYLOID ANGIOPATHY, ALZHEIMER'S DISEASE AND/OR ACUTE STROKE | HDL THERAPEUTICS, INC. (US) | 2019-11-14 | — | — | WO | claimed |
| US-20240382457-A1 | BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS | NOVARTIS PHARMA AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-12083101-B2 | Biaryl derivatives as YAP/TAZ-TEAD protein-protein interaction inhibitors | NOVARTIS AG (CH) | 2024-09-10 | — | — | US | disclosed |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148149-A2 | COMPOSITIONS AND METHODS FOR CONTROLLING GLUCOSE LEVELS | SIRTSEI PHARMACEUTICALS, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-11993593-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-05-28 | — | — | US | disclosed |
| US-20240158418-A1 | EGFR Degraders to Treat Cancer Metastasis to the Brain or CNS | C4 THERAPEUTICS, INC. (US) | 2024-05-16 | — | — | US | disclosed |
| US-20240148786-A1 | Methods for Preserving and Administering Pre-Beta High Density Lipoprotein Having a Predetermined Minimum Level of Degradation | HDL THERAPEUTICS, INC. | 2024-05-09 | — | — | US | disclosed |
| EP-4347044-A2 | EGFR DEGRADERS TO TREAT CANCER METASTASIS TO THE BRAIN OR CNS | C4 Therapeutics, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| WO-2003000381-A1 | HOLLOW FIBER CONTACTOR SYSTEMS FOR REMOVAL OF LIPIDS FROM FLUIDS | LIPID SCIENCES, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| WO-2003000373-A1 | SYSTEMS AND METHODS USING A SOLVENT FOR THE REMOVAL OF LIPIDS FROM FLUIDS | LIPID SCIENCES, INC. (US) | 2003-01-03 | — | — | WO | disclosed |
| US-6444616-B1 | HERBICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| US-6130225-A | Substituted p-trifluoromethylphenyluracils | BAYER AKTIENGESELLSCHAFT (DE) | 2000-10-10 | — | — | US | disclosed |
| EP-0923562-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AG (DE) | 1999-06-23 | — | — | EP | disclosed |
| US-5872113-A | COMPOUNDS FOR TREATMENT OF OSTEOPOROSIS AND BONE DISORDERS | SYNTEX (U.S.A.) INC. (US) | 1999-02-16 | — | — | US | disclosed |
| WO-1998006706-A1 | SUBSTITUTED P-TRIFLUOROMETHYLPHENYLURACILS | BAYER AKTIENGESELLSCHAFT (DE) | 1998-02-19 | — | — | WO | disclosed |
| EP-0808832-A2 | Fluorinated vitamin D3 analogs | F. HOFFMANN-LA ROCHE AG (CH) | 1997-11-26 | — | — | EP | disclosed |